Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,074
  • Shares Outstanding, K 17,012
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,140 K
  • EBIT $ -41 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.27

Options Overview Details

View History
  • Implied Volatility 384.23% (+116.90%)
  • Historical Volatility 117.96%
  • IV Percentile 87%
  • IV Rank 37.83%
  • IV High 899.17% on 11/19/25
  • IV Low 70.85% on 09/04/25
  • Expected Move (DTE 12) 1.2495 (105.89%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 29
  • Volume Avg (30-Day) 288
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 8,005
  • Open Int (30-Day) 9,529
  • Expected Range 0.0000 to 2.4295

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +66,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9190 +28.40%
on 11/17/25
1.5399 -23.37%
on 11/26/25
-0.1900 (-13.87%)
since 11/05/25
3-Month
0.9190 +28.40%
on 11/17/25
2.1900 -46.12%
on 10/20/25
-0.0500 (-4.07%)
since 09/05/25
52-Week
0.6500 +81.54%
on 05/08/25
5.9500 -80.17%
on 12/31/24
-2.4800 (-67.76%)
since 12/05/24

Most Recent Stories

More News
Citius Oncology Expands LYMPHIRâ„¢ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIRâ„¢, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

LYMPHIR now available nationwide

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology to Advance Commercial Launch of LYMPHIRâ„¢ with Verix AI Integration

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 1.1800 (-5.60%)
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 1.1800 (-5.60%)
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIRâ„¢ Commercial Launch

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR

CTXR : 1.1800 (-5.60%)
MCK : 808.62 (-0.68%)
CTOR : 1.1199 (+0.89%)
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

LD Micro Main Event XIX, October 19-21, 2025

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIRâ„¢

EVERSANA  to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CRANFORD, N.J. , Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")...

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CRANFORD, N.J. , Sept. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")...

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 1.3080
2nd Resistance Point 1.2824
1st Resistance Point 1.2312
Last Price 1.1800
1st Support Level 1.1544
2nd Support Level 1.1288
3rd Support Level 1.0776

See More

52-Week High 5.9500
Fibonacci 61.8% 3.9254
Fibonacci 50% 3.3000
Fibonacci 38.2% 2.6746
Last Price 1.1800
52-Week Low 0.6500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar